Tramadol is not approved or recommended for the treatment of anxiety by any major regulatory agency, and no controlled clinical trial has demonstrated that it is safe or effective for that purpose. The drug does have pharmacological properties that overlap with some antidepressants, which has fueled speculation and, unfortunately, self-medication. But the risks of using tramadol for anxiety are serious and well-documented: physical dependence can develop at standard prescribed doses, dangerous interactions with common anxiety medications are possible, and the drug lowers the seizure threshold in ways that other pain relievers do not.
Why Tramadol Looks Like an Antidepressant on Paper
Tramadol occupies an unusual pharmacological space. It is classified as an opioid analgesic, but unlike most opioids, it also blocks the reuptake of serotonin and norepinephrine in the brain. That second action is the same mechanism used by a class of antidepressants called SNRIs (drugs like venlafaxine and duloxetine), which are commonly prescribed for generalized anxiety disorder and other anxiety conditions. Imaging studies in primates have shown that tramadol blocks serotonin and norepinephrine transporters in a dose-dependent fashion, occupying roughly 40–72% of serotonin transporters and 7–73% of norepinephrine transporters depending on the dose.1Oxford Academic. Serotonin and Norepinephrine Transporter Occupancy of Tramadol in Nonhuman Primate Using Positron Emission Tomography At higher clinical doses, both transporters were blocked at rates above 70%, which is in the range typically associated with antidepressant efficacy.
This dual identity is what makes tramadol unusual among opioids and is why some clinicians and researchers have raised the question of whether it could have mood-related effects. A comprehensive review in the psychiatric literature has discussed the possibility that tramadol might be effective for certain anxiety and depressive states, particularly those involving feelings of social loss or betrayal, and has presented case reports to that effect.2Swiss Medical Weekly. Use of tramadol in psychiatric care: a comprehensive review and report of two cases But case reports are the weakest form of clinical evidence. No randomized, controlled trial has tested tramadol against placebo for any anxiety disorder in humans.
The Opioid Side and Emotional Regulation
Beyond its SNRI-like effects, tramadol activates mu-opioid receptors in the brain, which play a complicated role in emotional processing. Research on animals lacking functional mu-opioid receptors has found that these receptors actually promote anxiety-like and stress-related behavior: mice without them showed less anxiety on standard behavioral tests and had blunted stress hormone responses.3PubMed Central. Reduced emotional and corticosterone responses to stress in mu-opioid receptor knockout mice That finding suggests the relationship between opioid signaling and anxiety is not straightforward. Activating mu-opioid receptors does not simply reduce anxiety; it appears to modulate emotional reactivity in both directions.
Meanwhile, different opioid receptor subtypes have different relationships to anxiety. Research has shown that delta-opioid receptor activation has anxiolytic-like effects in rodents, while delta-opioid receptor deficiency is linked to increased anxiety-like behavior.4PubMed Central. Stress-Induced Changes in the Endogenous Opioid System Cause Dysfunction of Pain and Emotion Regulation Selective delta-opioid agonists have shown promise as potential anxiolytics and antidepressants in animal models.5PubMed. Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents Tramadol primarily hits mu-opioid receptors, not delta receptors, so the anxiety-reducing effects seen with delta activation do not translate directly to tramadol’s profile.
What many people experience as “anxiety relief” from tramadol is more likely the general euphoria and emotional blunting that comes with opioid activation. That feeling is real, but it is not the same thing as treating an anxiety disorder. It is closer to masking symptoms while creating a new and potentially worse problem.
Animal Studies Show Limited and Specific Effects
The most relevant animal research on tramadol and anxiety comes from pain models, not anxiety models. In one study, rats with surgically induced nerve injury (a model for chronic neuropathic pain) showed markedly increased anxiety-like behavior on a standard maze test, spending about 45% less time in the anxiety-provoking open areas compared to uninjured rats. Tramadol reversed this, increasing time in the open areas by roughly 67%.6PubMed Central. Tramadol reduces anxiety-related and depression-associated behaviors presumably induced by pain in the chronic constriction injury model of neuropathic pain in rats But here is the important detail: tramadol had no significant effect on anxiety-like behavior in uninjured rats. The anxiety reduction was specific to pain-induced anxiety, suggesting that tramadol was relieving the anxiety by relieving the pain, not by acting as a standalone anxiolytic.
This distinction matters. If your anxiety is being driven by unmanaged chronic pain, then effective pain control (of which tramadol might be a component under medical supervision) could reduce that anxiety as a downstream effect. But that is a very different proposition from taking tramadol to treat generalized anxiety, social anxiety, or panic disorder in the absence of a pain condition.
Physical Dependence at Normal Doses
One of the most concerning aspects of using tramadol for anything beyond its approved purpose is how quickly the body adapts to it. A controlled laboratory study in human volunteers demonstrated that physical dependence on tramadol develops at doses typically prescribed for mild to moderate pain.7PubMed Central. Physical dependence potential of daily tramadol dosing in humans The level of dependence increased with dose, and the dependence was mediated through opioid receptors, meaning it behaved like classic opioid dependence even though tramadol is often marketed as a “safer” or “milder” opioid.
For someone using tramadol to manage anxiety, this creates a trap. The drug provides short-term relief from uncomfortable feelings, the body adapts and requires the drug to feel normal, and stopping the drug produces withdrawal symptoms that include anxiety far worse than whatever prompted the use in the first place. This cycle is the textbook mechanism of opioid use disorder, and tramadol is no exception to it just because it has additional pharmacological properties.
A Withdrawal Unlike Other Opioids
Tramadol withdrawal has a distinctive and often confusing character. Because the drug acts on both opioid receptors and the serotonin system, stopping it can produce a mixed withdrawal picture. Clinical reports describe patients transitioning off tramadol who experienced symptoms resembling antidepressant discontinuation syndrome: brain zaps, dizziness, insomnia, and emotional instability, layered on top of more typical opioid withdrawal symptoms like sweating and restlessness.8Journal of Addiction Medicine. Tramadol Withdrawal in the Setting of Buprenorphine Induction: A Case Report
This mixed withdrawal profile has practical consequences. A clinician attempting to manage tramadol discontinuation with standard opioid withdrawal tools (like buprenorphine) may find that replacing the opioid component does not fully resolve the patient’s symptoms, because the serotonergic withdrawal persists. For someone who started taking tramadol for anxiety, the withdrawal experience can feel like the anxiety has returned with a vengeance, reinforcing the false belief that they “need” the drug.
Dangerous Interactions with Common Anxiety Medications
Here is where the risk picture becomes especially alarming for anyone considering tramadol for anxiety. People with anxiety disorders are frequently prescribed SSRIs (like sertraline, fluoxetine, or escitalopram) or SNRIs (like venlafaxine or duloxetine). Combining tramadol with either class of medication raises the risk of serotonin syndrome, a potentially life-threatening condition marked by agitation, rapid heart rate, muscle rigidity, high body temperature, and altered mental state.9PubMed Central. Interaction between tramadol and selective serotonin reuptake inhibitors: are doctors aware of potential risks in their prescription practice? The overall incidence of serotonin syndrome from this combination is low, and most cases are mild to moderate, but severe cases can be fatal, and the syndrome is far easier to prevent than to treat.
The risk is not uniform across all patients. Individuals who are poor metabolizers of the liver enzyme CYP2D6 appear to be at elevated risk, because their bodies handle tramadol’s serotonergic components differently.10PubMed. Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors Most people do not know their CYP2D6 status, which means the interaction is essentially a gamble. A person who takes tramadol for anxiety while already on an SSRI is playing that gamble every day, often without realizing it.
Seizure Risk Goes Up With Antidepressants
Tramadol lowers the seizure threshold more than other opioids, and this risk increases substantially when it is combined with other serotonergic medications. A large study of older nursing home residents found that combining tramadol with antidepressants that inhibit CYP2D6 was associated with a higher rate of seizures compared to combining tramadol with antidepressants that do not inhibit that enzyme.11PubMed Central. Risk of Seizure Associated With Concomitant Use of Tramadol and Antidepressants in Older Nursing Home Residents The effect was consistent across different subgroups.
In cases of tramadol intoxication (including accidental overdose), seizures are one of the most common serious complications. Research on tramadol poisoning cases has found that patients with any prior history of seizures were roughly four times more likely to seize after tramadol exposure, and higher doses were associated with more seizure episodes.12PubMed Central. Seizure Prevalence and Its Related Factors in Tramadol Intoxication; a Brief Report For someone self-medicating anxiety by escalating their tramadol dose (which tolerance makes increasingly tempting), the seizure risk is not theoretical.
What Overdose Looks Like
Tramadol overdose has been identified as one of the most frequent causes of drug poisoning in young male adults with a history of mental illness and substance use.13PubMed Central. Tramadol poisoning and its management and complications: a scoping review That demographic overlap between people with anxiety and people at risk for tramadol misuse is not coincidental. Symptoms of tramadol overdose include rapid heart rate, nausea, vomiting, reduced consciousness, and seizures. Cardiopulmonary arrest is the most common cause of death in tramadol poisoning cases.
A study of over 350 tramadol overdose cases found that the most frequent complications were high blood pressure (about 38%), rapid heart rate (about 25%), and seizures (roughly 15%). Taking more than 1,000 mg, being male, being between 30 and 49 years old, and actively trying to quit other drugs were all significantly associated with more severe outcomes.14Epidemiology and Health. Severe complications of tramadol overdose in Iran Fatal tramadol overdoses are uncommon when the drug is taken alone, but become much more likely when combined with other central nervous system depressants, especially benzodiazepines and alcohol.15Forensic Toxicology. A review on tramadol toxicity: mechanism of action, clinical presentation, and treatment People with anxiety disorders frequently take benzodiazepines or drink to manage their symptoms, making this a particularly dangerous overlap.
How Your Genetics Change the Risk
Tramadol is a prodrug, meaning the body must metabolize it into an active form (called O-desmethyltramadol, or M1) for its full opioid effects. The enzyme responsible for this conversion is CYP2D6, and people carry different genetic variants of this enzyme. Roughly 5–10% of people of European descent are “poor metabolizers” who convert tramadol slowly, while a smaller but significant fraction are “ultra-rapid metabolizers” who convert it very quickly.
This genetic variation has measurable consequences. In patients taking tramadol long-term, those with normal or enhanced CYP2D6 function produced more of the active M1 metabolite and showed significantly higher markers of oxidative stress and liver damage. People with the gene duplication variant (ultra-rapid metabolizers) developed moderate to severe liver toxicity within about 10–11 months of treatment, while those with normal function developed mild to moderate liver toxicity within 13–16 months.16PubMed. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity For someone using tramadol daily for anxiety over months or years (which is what chronic use for a chronic condition would require), this liver damage risk compounds over time and is invisible without blood monitoring.
The same genetic variation also affects the seizure and serotonin syndrome risks mentioned earlier. Poor metabolizers accumulate more of the parent drug (which is responsible for the serotonergic effects), while ultra-rapid metabolizers accumulate more of the opioid metabolite. Neither extreme is safe for off-label, unmonitored use.
Older Adults Face Compounded Risks
Anxiety disorders are common in older adults, and pain conditions that might lead to tramadol prescriptions are also more prevalent in this population. The overlap puts older people at particular risk for the consequences of tramadol use. In older adults, chronic tramadol use has been associated with increased rates of cardiovascular events, falls, hip fractures, emergency room visits, and hospitalization.17PubMed Central. Tramadol use and incident dementia in older adults with musculoskeletal pain: a population-based retrospective cohort study
A population-level study of older adults with osteoarthritis found that tramadol users generally had fewer adverse events than users of other opioids but significantly more adverse events than people not taking opioids at all. New tramadol users (as opposed to people already established on the drug) faced even higher risks, including increased mortality.18PubMed Central. Safety Events Associated with Tramadol Use Among Older Adults with Osteoarthritis The takeaway for an older person considering tramadol for anxiety is grim: the drug is already associated with meaningful safety risks even when used for its approved purpose (pain), and adding the complications of off-label psychiatric use makes the risk-benefit calculation substantially worse.
Why Self-Medication With Tramadol Persists
Despite all of this, tramadol self-medication for anxiety and mood problems is not rare. There are several reasons it persists. First, the drug is widely available and in many countries has been historically easier to obtain than stronger opioids. Second, the subjective experience of taking tramadol can include a sense of calm, sociability, and emotional warmth that feels like exactly what an anxious person wants. That experience is driven by the combined opioid and serotonergic effects, and it is genuinely pleasant for many people. Third, legitimate antidepressant and anti-anxiety medications typically take weeks to start working and can have side effects of their own (sexual dysfunction, weight gain, emotional flattening), while tramadol’s subjective effects are nearly immediate.
None of these reasons make tramadol a rational choice for anxiety. The immediate feel-good effect is the same quality that drives dependence. The accessibility that makes it tempting also means it is often used without medical oversight or drug interaction screening. And the delay before conventional treatments work is a feature of treatments that produce lasting change through receptor adaptation, not a flaw to be circumvented with a fast-acting opioid.
What Actually Works for Anxiety
Approved pharmacological treatments for anxiety disorders include SSRIs, SNRIs, buspirone, and in some cases benzodiazepines for short-term use. Cognitive behavioral therapy has a strong evidence base as both a standalone and adjunctive treatment. These options have decades of controlled trial data behind them, known side-effect profiles, established dosing guidelines, and regulatory approval. They are also genuinely effective for most patients when given adequate time and, if needed, dose adjustment.
If you are someone who has noticed that tramadol makes your anxiety feel better, the responsible next step is not to continue taking it for that purpose. It is to tell your prescriber what you have observed. That observation contains useful clinical information: it suggests your anxiety may respond to serotonin-norepinephrine modulation, which means an SNRI like venlafaxine or duloxetine could give you similar mood benefits without the opioid dependence, seizure risk, drug interactions, and liver damage that come with tramadol. The pharmacological overlap between tramadol and SNRIs is real, and a prescriber can use that information to guide treatment rather than letting it become a pathway to opioid misuse.
Tramadol and Premature Ejaculation
One off-label use of tramadol that has received more formal investigation than its use for anxiety is the treatment of premature ejaculation. Research has suggested that tramadol may be as effective as SSRIs for this purpose, with the hope that it carries a less burdensome side-effect profile for that specific, short-term application.19PubMed. Premature ejaculation: current medical treatment and new directions This use is relevant here because it is sometimes conflated with broader psychiatric use in online discussions. Taking a low dose of tramadol before intercourse is a fundamentally different exposure pattern than taking it daily for chronic anxiety: the dependence risk, drug interaction window, and seizure risk all scale with frequency and duration of use. The existence of a credible off-label use for one condition does not validate its use for a different condition under entirely different dosing circumstances.